S&P 500 Healthcare Sector SEC Filings — July 30, 2026

Revenue grew 17% YoY to $4.29B, Dupixent global sales surged 38% to $6.0B, and Sanofi Development Balance fully repaid—boosting collaboration profits from Q3 2026. Non-GAAP EPS rose 8% to $14.29.

Growth Portfolio revenue jumped 15% to $7.6B, Opdivo Qvantig grew >200% to $261M, and full-year non-GAAP EPS guidance raised to $6.75-7.00 (up 40% YoY). GAAP EPS surged 153% to $1.62.

Total revenues up 7% YoY to $71.7B, adjusted income from operations up 6% to $2.1B, and full-year 2026 adjusted EPS guidance raised to at least $30.45. Diluted EPS grew 10% YoY to $6.29.

Sales grew 5% YoY to $2.96B across all segments, Medical Products & Therapies up 7%, and full-year 2026 outlook raised to 3-4% reported sales growth.

GAAP gross margin on net product sales collapsed 500 bps to 78% from 83% YoY due to a temporary manufacturing interruption in Ireland—a significant profitability headwind.

Evernorth Health Services pre-tax adjusted income declined 2% YoY, total customer relationships fell 3% from year-end 2025, and pharmacy customers dropped 4%. Company plans to exit Individual and Family Plans by Jan 2027.

Legacy Portfolio revenues declined 4% (5% ex-FX) to $5.4B, Revlimid fell 49% to $425M, and GAAP gross margin contracted 120 bps to 71.3%.

Adjusted diluted EPS declined 5% YoY to $0.56 despite revenue growth, due to higher-cost inventory and unfavorable cost reclassifications.

GAAP net income declined 7% to $1.297B (EPS $12.23) despite 17% revenue growth, as operating expenses grew faster than revenue. Effective tax rate jumped to 15.1% from 8.4% YoY.

CVP, JAPAC Markowitz Wayne sold 146 shares at $86.03 (~$12.6K)—a small insider sale, but negative signal from a regional executive.

BlackRock increased its passive stake by 8.1% to 37.7M shares (9.0% ownership), signaling institutional confidence in the animal health sector.

Operating cash flow remained thin at $710M in H1 2026, and share repurchases were slashed 90% to $250M from $2.58B in H1 2025—a dramatic shift in capital allocation.

GAAP gross margin on net product sales fell 500 bps YoY to 78% from 83%, driven by unabsorbed manufacturing costs from a temporary interruption at the Limerick, Ireland facility. Production has resumed, but margin recovery timeline is uncertain.

Total customer relationships fell 3% from year-end 2025, with pharmacy customers down 4%. Evernorth Health Services pre-tax adjusted income declined 2% YoY—a key growth engine is stalling.

Legacy Portfolio revenues declined 4% (5% ex-FX) to $5.4B, with Revlimid down 49% to $425M. Patent expirations continue to erode the base business.

Medical Care Ratio (MCR) increased to 84.5% from 83.2% YoY, reflecting higher prior year risk adjustment benefits. This signals potential pricing or claims cost pressure.

Adjusted diluted EPS fell 5% YoY to $0.56 despite 5% revenue growth, driven by higher-cost inventory and unfavorable cost reclassifications. Full-year adjusted EPS guidance of $1.95-$2.15 implies potential further compression.

Acquired in-process R&D expenses surged 1,170% to $127.0M from $10.0M YoY, and GAAP R&D expenses increased 15% to $3.0B at Bristol Myers. The sector is spending aggressively on pipeline deals, risking ROI.

Total comprehensive income fell sharply to $1.11B from $1.41B in Q2 2025, driven by a $1.01B after-tax loss on long-duration insurance liability adjustments—a significant balance sheet risk.

Comprehensive income attributable to Baxter stockholders plunged 62% YoY to $109M, driven by a large unfavorable currency translation adjustment. First half comprehensive income dropped 90.4% YoY to $46M.

Bayer collaboration revenue declined 33% YoY to $276M, indicating potential weakness in partnered products.

Net investment losses of $69M in Q2 2026 vs. gains of $52M in Q2 2025, adding to earnings volatility.

Global net sales surged 38% to $6.0B, and the Sanofi Development Balance is fully repaid, boosting collaboration profits from Q3 2026 onward. Expect significant margin expansion in H2 2026.

Growth Portfolio revenue jumped 15% to $7.6B, with Opdivo Qvantig growing >200% to $261M and Eliquis up 22% to $4.5B. Full-year revenue guidance raised to ~$49.0-50.0B.

U.S. net sales grew 52% to $596M, and Libtayo global net sales rose 30% to $489M. Strong product momentum supports premium valuation.

Medical Products & Therapies segment sales grew 7% reported and 5% organic, driven by Infusion Therapies & Platforms and Advanced Surgery. Tariff refund benefit of $0.11 per share provides a tailwind.

Despite reduced buybacks, Cigna raised full-year adjusted EPS guidance to at least $30.45, and diluted EPS grew 10% YoY to $6.29. The stock may be undervalued if customer attrition stabilizes.

BlackRock increased its passive stake by 8.1% to 37.7M shares (9.0% ownership), signaling strong institutional confidence in the animal health sector.

Trading at a potential discount given Growth Portfolio momentum and raised guidance. Non-GAAP EPS grew 40% to $2.04, and full-year guidance implies continued acceleration.

Aggressive buybacks of $1.96B in H1 2026 demonstrate management's confidence in intrinsic value, despite cash reserves declining to $2.46B from $3.12B.

Free cash flow was $181M in Q2 and $257M in H1 2026, providing flexibility for debt reduction or strategic investments.

Planned exit from Individual and Family Plans medical business by Jan 2027 could reduce earnings volatility and improve margins, focusing on higher-growth segments.

5/6 reporting companies posted revenue growth (avg ~8% YoY), but 3/6 saw margin compression (Regeneron -500 bps gross margin, Bristol Myers -120 bps, Cigna MCR +130 bps). Top-line strength is not translating to bottom-line gains. [IMPLICATION: Focus on companies with pricing power and cost control]

Cigna slashed buybacks 90% YoY to $250M, while Regeneron accelerated repurchases to $1.96B in H1 2026. Bristol Myers raised guidance but faces legacy portfolio headwinds. The sector is split between returning capital and conserving cash. [IMPLICATION: Monitor cash flow sustainability and management priorities]

Regeneron's IPR&D expenses surged 1,170% to $127M, and Bristol Myers' R&D increased 15% to $3.0B. The sector is investing heavily in pipeline growth, but ROI remains uncertain. [IMPLICATION: Watch for pipeline milestones and regulatory catalysts]

Cigna is exiting Individual and Family Plans, Bristol Myers is shifting from Legacy to Growth Portfolio, and Baxter is navigating tariff impacts. Strategic repositioning creates both risks and opportunities. [IMPLICATION: Identify companies with clear strategic direction and execution track record]

BlackRock increased its Zoetis stake by 8.1%, and Regeneron's aggressive buybacks signal management conviction. However, insider selling at Edwards Lifesciences (small) and Cigna's customer attrition warrant caution. [IMPLICATION: Follow the smart money, but differentiate between passive and active signals]

Baxter's comprehensive income plunged 62% YoY due to unfavorable currency translation, and Regeneron's effective tax rate jumped to 15.1% from 8.4%. Macro factors are impacting reported earnings. [IMPLICATION: Focus on organic operational performance and hedge exposure]

Q3 2026 results will be critical to assess margin recovery from the Ireland manufacturing interruption and the impact of the Sanofi Development Balance repayment on collaboration profits. [Date: Late October 2026]

Monitor customer relationship trends in Q3 2026, especially pharmacy customers (down 4% from year-end 2025) and the impact of the Individual and Family Plans exit by Jan 2027. [Date: Ongoing]

Track Revlimid revenue trajectory (down 49% YoY) and the pace of Growth Portfolio offset. Full-year guidance of $49-50B revenue implies H2 acceleration. [Date: Q3 2026 report]

Adjusted EPS declined 5% YoY despite revenue growth. Watch for improvement in H2 2026 as higher-cost inventory cycles out and tariff refunds provide a tailwind. [Date: Q3 2026 report]

The small insider sale by CVP Markowitz Wayne may be insignificant, but any further insider selling at the C-suite level would be a red flag. [Date: Ongoing]

With $1.96B spent in H1 2026 and cash reserves declining to $2.46B, monitor the pace of buybacks in H2 2026 for signals on management's view of valuation. [Date: Q3 2026 report]

Thin operating cash flow of $710M in H1 2026 and reduced buybacks suggest cash constraints. Watch for improvement in H2 2026 as the company exits the Individual and Family Plans business. [Date: Q3 2026 report]

With BlackRock holding 9.0% passive ownership, any changes in this position (increase or decrease) would signal institutional sentiment shifts in the animal health sector. [Date: Next 13F filing]